<DOC>
	<DOCNO>NCT00841581</DOCNO>
	<brief_summary>Patients Pigment Epithelial Detachments secondary Age-Related Macular Degeneration ( AMD ) receive intravitreal Lucentis monthly 6 month hope improve visual acuity baseline evaluation .</brief_summary>
	<brief_title>Lucentis Treat Pigment Epithelial Detachment</brief_title>
	<detailed_description>Background : Exudative Age Related Macular Degeneration ( AMD ) result significant severe visual loss leave untreated documented natural history observational arm study macular photocoagulation study ( MPS ) Tap VIP study Visudyne . It also clear however , different lesion type ( classify intravenous fluorescein angiography ( ( IVFA ) ) occult , minimally classic predominately classic ) different natural history different response treatment . The recent introduction anti-VEGF agent Macugen Lucentis significantly advance ability treat AMD agents show clear efficacy across lesion subtypes regardless lesion composition . A clear absence literature clinical outcome exist however fibrovascular pigment epithelial detachment ( PED ) . PED represent form exudative AMD clearly behave unique distinctive manner compare lesion ( ) describe . As standard exclusion criterion within major AMD trial , lesion composition IVFA subtype acceptable long less 50 % lesion compose blood pigment epithelial detachment . This result notable absence clinical literature response predominately PED type lesion current standard care anti-VEGF agent . In effort address absence , prospective evaluation response predominately PED type lesion Lucentis , current gold standard therapy need . Study design : Thirty two patient recruit participate base Inclusion / Exclusion Criteria describe later paragraph . Patients receive monthly intravitreal Lucentis injection every 33 day ( +/- 4 day ) 6 month . At 6 month , patient evaluate base ETDRS Visual Acuity OCT determine response Lucentis therapy . Patients experience visual improvement baseline ETDRS acuity ( defined net gain baseline 10 letter ) show reduction height fibrovascular PED lesion OCT great 30 % baseline OCT deem Lucentis non-responders . These patient receive intravitreal Lucentis injection , undergo re-evaluation 12 month . Patients deem responder , continue OCT-guided 6 month active treatment period . In patient , iL administer evidence visual loss 1 line ( Snellen ) 6-month visit value , evidence intraretinal subretinal fluid OCT , growth PED great 50 micron 6-month visit OCT value . Non-responders evaluate 12-month final visit . Baseline IVFA , OCT , Snellen Visual Acuity , ETDRS refraction contrast sensitivity obtain along comprehensive ophthalmological examination . Complete diagnostic assessment include fluorescein angiography , OCT visual function test repeat 3 , 6 12 month baseline treatment . In addition , patient continue active intravitreal Lucentis therapy beyond 6 month ( responder ) , undergo monthly OCT examination ( month 6 11 ) ophthalmic safety examination order determine need Lucentis administration . At final , Month 12 visit , patient undergo ophthalmic examination , OCT , ETDRS refraction , Snellen Visual Acuity contrast sensitivity .</detailed_description>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Predominantly PED type lesion classify IVFA OCT secondary AMD . 2 . PED geometric center foveal avascular zone . 3 . Evidence recent disease progression suggest one following : subretinal lipid cystic macular edema , subretinal hemorrhage , vision loss within last 3 month document lesion growth FA previous 6 month . 4 . Visual acuity 20/40 20/800 study eye Equivalent Early Treatment Diabetic Retinopathy Study ( ETDRS ) eye chart score 5 75 letter 2 meter . 5 . Ambulatory Vision fellow eye 6 . Willingness ability participate provide write informed consent . 1 . Individuals choroidal neovascularization cause AMD . 2 . Patients physically unable tolerate intravenous fluorescein angiography 3 . Any intraocular surgery within 2 month study eye . 4 . Prior retinal vitreous surgery include vitrectomy scleral buckling study eye . 5 . Any significant ocular disease compromise could compromise vision study eye confound analysis primary outcome . 6 . Individuals physical mental disability prevent accurate vision test . 7 . History treatment CNVM study eye extrafoveal confluent laser photocoagulation . 8 . Prior photodynamic therapy CNV . 9 . Any patient recent history new onset cardiac disease thromboembolic CNS event past . 10 . Women childbearing potential two form effective contraception trial least 60 day follow last dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Age Related Macular Degeneration</keyword>
	<keyword>Pigment Epithelial Detachment</keyword>
	<keyword>Intravitreal Detachment</keyword>
	<keyword>Anti-VEGF</keyword>
</DOC>